.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,351,414

« Back to Dashboard

Claims for Patent: 7,351,414

Title:Method of reducing the risk of bone fracture
Abstract:The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracture, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fractur and/or reduce the incidence of non-vertebral fracture.
Inventor(s): Gaich; Gregory A. (Indianapolis, IN), Dere; Willard H. (Westlake Village Ventura, CA), Hock; Janet M. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:11/684,996
Patent Claims: 1. A method for the treatment of a woman with osteoporosis and at risk for bone fracture comprising administering to said woman human parathyroid hormone (1-34) in a daily dose of 20 .mu.g, without concurrent administration of an antiresorptive agent other than vitamin D or calcium, said treatment reducing the risk of vertebral and nonvertebral bone fracture.

2. The method of claim 1, wherein the osteoporosis is selected from advanced-stage osteoporosis, spinal osteoporosis, and steroid-induced osteoporosis.

3. A method for the treatment of a man with osteoporosis and at risk for bone fracture comprising administering to said man human parathyroid hormone (1-34) in a daily dose of 20 .mu.g, without concurrent administration of an antiresorptive agent other than vitamin D or calcium, said treatment reducing the risk of vertebral and non-vertebral bone fracture.

4. The method of claim 3 in which said man has hypogonadal osteoporosis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc